Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience

• 영문명: Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience
• 발행기관: 대한방사선종양학회
• 저자명: Ángel L. Sánchez-Iglesias Virginia Morillo-Macías Ana Santafé-Jiménez Carlos Ferrer-Albiach
• 간행물 정보: 『대한방사선종양학회지』제40권 제3호, 192~199쪽, 전체 8쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 2022.09.30

영문 초록

Purpose: Ablative treatment of oligometastases has shown survival benefit with certain tumors, although these effects still are to be demonstrated in prostate cancer. Materials and Methods: We analysed the toxicity and clinical control results obtained in patients with bone-only oligometastatic prostate cancer treated with stereotactic ablative radiotherapy (SABR). Retrospective study on patients with metachronous oligoprogression and synchronous de novo bone-only oligometastatic prostate cancer treated with SABR and androgen deprivation therapy. Results: Treatment schedules varied according to location and organs at risk, with biologically equivalent dose (BED) ≥100 Gy. Fifty-five bone lesions (31 patients) were treated and evaluated for toxicity, local control, progression-free survival (PFS), and overall survival (OS). After a 41-month follow-up, there was minimal acute or chronic toxicity and no G3 toxicity. The local control at 3 and 5 years was 100% and 87.1%, respectively. Median PFS and OS were 43 and 98 months, respectively. The best result in PFS was obtained with BED ≥230 Gy, delaying time to the next systemic therapy by 28.5 months. Conclusion: The use of SABR in bone oligometastases of prostate cancer is safe with minimal toxicity and excellent results in local control and PFS, delaying the start of the next systemic therapy.

목차

Introduction

Materials and Methods

Results

Discussion and Conclusion

Statement of Ethics

Conflict of Interest

Financial Support

Author Contributions

Data Availability Statement

References

키워드

Stereotactic body radiotherapy Bone oligometastases Prostate cancer Next systemic therapy